Injectable Drug Delivery Devices Market Set for Steady Expansion by 2032, Driven by Innovation and Growing Surgical Volumes | DelveInsight

The injectable drug delivery devices market was valued at USD 19.63 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 11.26%, reaching approximately USD 37.22 billion by 2030. This growth is largely driven by the rising prevalence of chronic diseases such as cancer, diabetes, and cardiovascular conditions. Additional contributing factors include the growing demand for self-injection devices, expansion of the biologics and biosimilars market, increased emphasis on patient adherence to treatment regimens, and ongoing technological innovations in drug delivery solutions.

DelveInsight's Injectable Drug Delivery Devices Market Insights report provides the current and forecast market analysis, individual leading Injectable Drug Delivery Devices companies' market shares, challenges, Injectable Drug Delivery Devices market drivers, barriers, and trends, and key Injectable Drug Delivery Devices companies in the market.

Request for a sample report @ https://www.delveinsight.com/report-store/injectable-drug-delivery-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Key Takeaways from the Injectable Drug Delivery Devices Market Report
The Injectable Drug Delivery Devices market is projected to grow at a moderate CAGR from 2025 to 2032.
As per DelveInsight estimates, North America is anticipated to dominate the global Injectable Drug Delivery Devices market during the forecast period.
Notable Injectable Drug Delivery Devices companies such as Eli Lilly and Company, Biocon, Becton, Dickinson & Company, West Pharmaceutical Services, Inc., Johnson & Johnson, Antares Pharma, AbbVie Inc., Pfizer Inc., Mylan N.V., Vetter Pharma-Fertigung GmbH & Co.KG, and several others are currently operating in the Injectable Drug Delivery Devices market.
On November 13, 2024, Simulations Plus, Inc. announced that it had received a grant from the U.S. FDA to utilize physiologically based pharmacokinetic (PBPK) modeling in its GastroPlus® platform to develop and validate mechanistic in vitro-in vivo correlations (IVIVCs) for long-acting injectable (LAI) technologies. This initiative is being carried out in collaboration with the Department of Pharmaceutical Sciences at the University of Connecticut's School of Pharmacy.
On August 21, 2022, Zydus Cadila received approval from the Drug Controller General of India (DCGI) for its needle-free, plasmid DNA-based COVID-19 vaccine.
On November 13, 2019, Stevanato Group partnered with Duoject to collaborate on the production and promotion of the 'Maverick' auto-injector, designed for emergency use.
On October 21, 2019, Becton Dickinson and Company, a leading global medical technology firm, introduced the BD InteviaTM 1mL two-step disposable autoinjector-a versatile platform that integrates an autoinjector with a pre-fillable syringe into a single, unified system.


To read more about the latest highlights related to the Injectable Drug Delivery Devices market, get a snapshot of the key highlights entailed in the Global Injectable Drug Delivery Devices Market Report https://www.delveinsight.com/report-store/injectable-drug-delivery-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr


Injectable Drug Delivery Devices Overview

Injectable drug delivery devices are medical tools designed to administer medications directly into the body via injection. These devices play a critical role in delivering a wide range of therapies, including biologics, vaccines, insulin, and chemotherapy agents, especially for chronic and acute conditions such as diabetes, cancer, and cardiovascular diseases.

Injectable Drug Delivery Devices Market Insights

North America is anticipated to hold the largest share of the injectable drug delivery devices market. This dominance is largely attributed to the increasing prevalence of chronic diseases, ongoing research and development activities, supportive government initiatives aimed at raising awareness about chronic conditions, and rising healthcare expenditure-all of which are expected to significantly contribute to market growth throughout the forecast period.

According to the American Cancer Society, approximately 1.9 million new cancer cases were diagnosed in the U.S. in 2021. Data from the Centers for Disease Control and Prevention (CDC) reported 1,752,735 new cancer cases in 2019. Additionally, Globocan 2021 reported around 61,152 new leukemia cases in 2020 in the U.S., along with 73,652 cases of non-Hodgkin lymphoma and 8,107 new cases of Hodgkin lymphoma the same year.

Furthermore, the American Heart Association projected in 2021 that by 2035, over 130 million adults in the U.S. will be living with some form of heart disease.

Given this substantial patient population, the demand for injectable drug delivery devices in the United States is expected to rise significantly over the forecast period.

To know more about why North America is leading the market growth in the Injectable Drug Delivery Devices market, get a snapshot of the Injectable Drug Delivery Devices Market Outlook https://www.delveinsight.com/report-store/injectable-drug-delivery-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr


Injectable Drug Delivery Devices Market Dynamics

According to the World Health Organization (2022), there were an estimated 2.26 million cases of breast cancer, 2.21 million cases of lung cancer, 1.93 million cases of colorectal cancer, 1.41 million cases of prostate cancer, and 1.09 million cases of stomach cancer reported worldwide in 2020. Additionally, the International Diabetes Federation's *Diabetes Atlas* (2022) indicated that 537 million adults were living with diabetes in 2021, with projections rising to 643 million by 2030 and 783 million by 2045.

The British Heart Foundation (2022) also reported that in 2019, around 550 million people globally-roughly 1 in every 14 individuals-were affected by heart and circulatory diseases, including about 290 million women and 260 million men.

The growing global burden of chronic illnesses such as cancer, diabetes, and cardiovascular diseases has significantly increased the need for effective treatment options. This has resulted in a higher volume of procedures like chemotherapy and insulin delivery, thereby propelling the growth of the injectable drug delivery market. These delivery systems offer advantages such as targeted, efficient, and accurate drug administration, making them essential tools in managing complex, long-term conditions.

Furthermore, technological advancements-such as needle-free injectors, prefilled syringes, auto-injectors, and microneedle systems-are enhancing patient experience by improving ease of use, accuracy, and adherence to treatment, all of which are accelerating market expansion.

Injectable Drug Delivery Devices Market Drivers:

Increasing incidences of chronic conditions such as cancer, diabetes, and cardiovascular disorders among others
Increase in demand for self-injectors
Increase in the biologics and biosimilar market
Rising need and demand for patient compliance to treatment
Rising innovations and technological advancement in this arena

Get a sneak peek at the Injectable Drug Delivery Devices market dynamics @ https://www.delveinsight.com/report-store/injectable-drug-delivery-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr


Coverage: Global
Study Period: 2022 to 2032
Key Injectable Drug Delivery Devices Companies: Eli Lilly and Company, Biocon, Becton, Dickinson & Company, West Pharmaceutical Services, Inc., Johnson & Johnson, Antares Pharma, AbbVie Inc., Pfizer Inc., Mylan N.V., Vetter Pharma-Fertigung GmbH & Co.KG, and others.

Which MedTech key players in the Injectable Drug Delivery Devices market are set to emerge as the trendsetter, explore @ Injectable Drug Delivery Devices Companies https://www.delveinsight.com/report-store/injectable-drug-delivery-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr


Table of Contents

1. Injectable Drug Delivery Devices Market Report Introduction
2. Injectable Drug Delivery Devices Market Executive Summary
3. Competitive Landscape
4. Regulatory Analysis
5. Injectable Drug Delivery Devices Market Key Factors Analysis
6. Injectable Drug Delivery Devices Market Porter's Five Forces Analysis
7. Injectable Drug Delivery Devices Market Layout
8. Injectable Drug Delivery Devices Market Company and Product Profiles
9. KOL Views
10. Project Approach
11. About DelveInsight
12. Disclaimer & Contact Us

Contact Info:
Kritika Rehani
Assistant Manager, Marketing & Branding
krehani@delveinsight.com
info@delveinsight.com
+14699457679

About DelveInsight
DelveInsight is a premier healthcare business consultant and market research firm, specializing in life sciences. We empower pharmaceutical companies with comprehensive end-to-end solutions designed to enhance performance and drive growth.
Our expert healthcare consulting services offer in-depth market analysis, helping businesses accelerate growth and navigate challenges with actionable, results-driven strategies.

This release was published on openPR.